Core Insights - Biomap, a biotechnology start-up co-founded by Baidu's Robin Li, claims to have surpassed AlphaFold in commercializing AI models for drug discovery [1][2] - Wei Liu, Biomap's CEO, noted a "reverse" in the technological gap between Biomap and AlphaFold, indicating a shift in competitive dynamics [1] - While AlphaFold is recognized for its academic influence, Biomap asserts its lead in commercialization and project development [2] Company Developments - Biomap's xTrimo models reportedly demonstrated greater accuracy than AlphaFold 3 in analyzing interactions between 70 antibodies and 44 single-domain antibodies [4] - The company received funding from the Hong Kong Investment Corporation in June last year, supporting its growth and development [4] - Biomap has initiated an accelerator program, BioMap InnoHub, aimed at enhancing Hong Kong's biotech ecosystem, with plans to expand to over 50 projects and 20 companies by 2030 [5] Strategic Partnerships - Biomap co-founded BioGend Science with Legend Capital, focusing on developing drug pipelines utilizing Biomap's AI platform and local research resources [6] - The partnership aims to further Biomap's commercialization efforts in bringing new drugs to market [5][6]